COVID-19 drug trial halted early: did aprepitant help?
NCT ID NCT04470622
First seen Mar 09, 2026 · Last updated May 21, 2026 · Updated 11 times
Summary
This study tested whether the drug aprepitant, given as an injection, could help hospitalized adults with COVID-19 recover faster. The trial was stopped early after enrolling only 27 participants. The goal was to see if the drug reduced the need for breathing support and shortened hospital stays.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Helen Keller Hospital
Sheffield, Alabama, 35660, United States
-
University of California, Irvine Medical Center
Orange, California, 92868, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.